Eli Lilly’s (LLY) products are classified into two business segments: Human Pharmaceutical Products and Animal Health Products.
The above chart compares the segments’ quarterly revenues since 1Q17.
Human Pharmaceutical Products
The Human Pharmaceutical Products segment includes oncology, cardiology, neuroscience, endocrinology, and other products. It contributed 86.6% of the company’s total revenues in 1Q18. Total sales for the segment increased 11% to $4.9 billion in 1Q18 compared to 1Q17. Growth was driven by the strong performances of Alimta, Basaglar, Cyramza, Humalog, Humulin, Jardiance, Lartruvo, Olumiant, Taltz, Trajenta, and Trulicity.
US sales increased 10% in 1Q18, driven by an 8% positive impact of prices and a 2% growth in volumes. Sales from European markets increased 17%, driven by a 7% growth in sales volumes and a 15% positive impact of foreign exchange, partially offset by a 5% decrease in prices. Sales from Japanese markets increased 6%, driven by a 5% increase in volumes and a 5% positive impact of foreign exchange, partially offset by a 3% decrease in prices.
Elanco: The Animal Health Products segment
Eli Lilly operates its Animal Health Products segment through Elanco. In 1Q18, Elanco contributed 13.4% of the company’s total revenues with revenues of $761.3 million, a 1% decline compared to 1Q17. The decline was driven by an 8% decrease in volumes, offset by a 3% positive impact of foreign exchange and a 5% positive impact of higher realized prices.
At constant exchange rates, the Human Pharmaceutical Products segment reported a 7% growth in revenues, while the Animal Health Products segment reported a 4% decline. Overall revenues increased 5% at constant exchange rates in 1Q18.
Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!